Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Left Ventricular Hypertrophy in Type 2 Diabetes
2016-000715-33Phase 4Completed
- Sponsor
- University of Dundee
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), left ventricular hypertrophy (LVH) and cardiac disease comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Left ventricular mass by cardiac MRI. Started May 2019; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)left ventricular hypertrophy (LVH)cardiac disease
Beyond the preview
Go deeper on 2016-000715-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000715-33.